Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1021/acs.analchem.5c06259

http://scihub22266oqcxt.onion/10.1021/acs.analchem.5c06259
suck pdf from google scholar
41384307!?!41384307

suck abstract from ncbi

pmid41384307      Anal+Chem 2025 ; ? (?): ?
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor Cells #MMPMID41384307
  • Zeng T; Li B; Xu J; Sun Y; Xiao Y; Zhou Z; Hua Y; Wu S; Shi H; Li G; Yin Y
  • Anal Chem 2025[Dec]; ? (?): ? PMID41384307show ga
  • The nondestructive capture and direct identification of circulating tumor cells (CTCs) have emerged as the critical technologies in modern oncology for oncology research, clinical diagnosis, and personalized therapy optimization. However, technical challenges still exist due to the extreme rarity and significant phenotypic heterogeneity. Herein, we present an innovative biomimetic detection platform engineered by integrating platelet membrane-camouflaged magnetic beads (PM-MBs) with rolling circle amplification (RCA)-synthesized aptamer-based polyvalent antibody mimics (PAMs), which is abbreviated as PM-PAM platform. This dual-functional PM-PAM platform demonstrates exceptional CTC capture efficiency (>90%) while enabling instrument-free visual detection of trophoblast cell surface antigen 2 (Trop-2) expression through metal-organic framework (MOF) nanozyme-based colorimetric signals. Triple-negative breast cancer (TNBC) patients undergoing sacituzumab govitecan (SG) therapy suggests CTCs can be successfully detected. Meanwhile, concurrent visual assessment of Trop-2 expression levels on captured cells can be realized. With the unique advantages of cell viability preservation, 100% diagnostic specificity, modular design adaptability, and cost-effectiveness, the PM-PAM platform establishes a new paradigm for liquid biopsy applications. This technology also shows the particular promise for monitoring antibody-drug conjugate (ADC) treatment efficacy through dynamic Trop-2 expression analysis in breast cancer management.
  • ?


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box